Insider Transactions in Q2 2024 at Crinetics Pharmaceuticals, Inc. (CRNX)
Insider Transaction List (Q2 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 28
2024
|
Marc Wilson CFO |
SELL
Open market or private sale
|
Direct |
32,129
-22.43%
|
$1,381,547
$43.61 P/Share
|
|
Jun 28
2024
|
Marc Wilson CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
32,129
+18.32%
|
$289,161
$9.28 P/Share
|
|
Jun 26
2024
|
Jeff E. Knight Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
956
-1.79%
|
$42,064
$44.38 P/Share
|
|
Jun 25
2024
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,000
-3.59%
|
$135,000
$45.37 P/Share
|
|
Jun 24
2024
|
Dana Pizzuti Chief Med and Dev Officer |
SELL
Open market or private sale
|
Direct |
9,500
-25.48%
|
$427,500
$45.73 P/Share
|
|
Jun 24
2024
|
Dana Pizzuti Chief Med and Dev Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,500
+20.31%
|
$152,000
$16.89 P/Share
|
|
Jun 21
2024
|
James Hassard Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
15,000
-33.89%
|
$660,000
$44.66 P/Share
|
|
Jun 21
2024
|
James Hassard Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+25.31%
|
$285,000
$19.73 P/Share
|
|
Jun 10
2024
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,000
-3.46%
|
$129,000
$43.86 P/Share
|
|
Jun 07
2024
|
Matthew K Fust |
BUY
Grant, award, or other acquisition
|
Direct |
3,400
+13.42%
|
-
|
|
Jun 07
2024
|
Weston Nichols |
BUY
Grant, award, or other acquisition
|
Direct |
3,400
+26.56%
|
-
|
|
Jun 07
2024
|
Stephanie Okey |
BUY
Grant, award, or other acquisition
|
Direct |
3,400
+26.56%
|
-
|
|
Jun 07
2024
|
Coelho Rogerio Vivaldi |
BUY
Grant, award, or other acquisition
|
Direct |
3,400
+19.1%
|
-
|
|
Jun 07
2024
|
Caren Deardorf |
BUY
Grant, award, or other acquisition
|
Direct |
3,400
+26.56%
|
-
|
|
Jun 07
2024
|
Wendall Wierenga |
BUY
Grant, award, or other acquisition
|
Direct |
3,400
+3.02%
|
-
|
|
Jun 07
2024
|
Camille L Bedrosian |
BUY
Grant, award, or other acquisition
|
Direct |
3,400
+26.56%
|
-
|
|
May 28
2024
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,000
-3.35%
|
$141,000
$47.49 P/Share
|
|
May 10
2024
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,000
-3.24%
|
$147,000
$49.43 P/Share
|
|
May 08
2024
|
Richard Scott Struthers President & CEO |
SELL
Open market or private sale
|
Direct |
107,448
-29.44%
|
$5,264,952
$49.4 P/Share
|
|
May 08
2024
|
Richard Scott Struthers President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
107,448
+22.75%
|
$967,032
$9.28 P/Share
|
|
Apr 18
2024
|
Richard Scott Struthers President & CEO |
SELL
Bona fide gift
|
Direct |
350
-0.14%
|
-
|
|
Apr 15
2024
|
Dana Pizzuti Chief Med and Dev Officer |
SELL
Open market or private sale
|
Direct |
14,375
-34.1%
|
$632,500
$44.47 P/Share
|
|
Apr 15
2024
|
Dana Pizzuti Chief Med and Dev Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,375
+25.43%
|
$230,000
$16.89 P/Share
|
|
Apr 15
2024
|
Richard Scott Struthers President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+7.2%
|
$20,000
$1.91 P/Share
|
|
Apr 04
2024
|
Richard Scott Struthers President & CEO |
SELL
Open market or private sale
|
Direct |
40,951
-14.69%
|
$2,006,599
$49.17 P/Share
|
|
Apr 04
2024
|
Richard Scott Struthers President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
40,951
+12.81%
|
$368,559
$9.28 P/Share
|